From mitochondrial networks that silently rebalance fusion and fission, to chromosomes that only reveal their fate in the minutes after division, live-cell imaging uncovers dynamics that static snapshots miss entirely. We explore three examples, including how tracking RNA therapeutic vehicles as they transit and escape endosomal compartments in real time resolves ambiguity that even super-resolution imaging of fixed cells can’t overcome.
By looking beyond the diffraction limit, we have established a method to quantitatively distinguish low-grade breast cancers that appear identical by traditional means. Ultimately, this nanoscale insight could expand access to novel HER2-targeted therapies by reliably identifying low expressing cohorts that would benefit from intervention.
Lipid nanoparticles (LNPs) are recognised as a leading delivery platform following clinical success in vaccine and therapeutic applications. Medicines Discovery Catapult (MDC) has built a preclinical platform to evaluate LNPs against two major challenges in the field. In this blog, Lead Scientist, Dr Phil Auckland, presents a case study of this workflow using intravenously administered LNPs encapsulating mRNA, which differentially target four major liver cell types.
Opening new avenues for RNA therapeutics through a preclinical screening and optimisation platform. In this blog, Lead Scientist Dr Phil Auckland describes how applying this platform to a library of 4,500 lipid nanoparticle (LNP) formulations enabled the identification of novel candidates with desirable mechanistic properties and in vivo functionality. Furthermore, we show that integrating multiple in vitro readouts can enhance prediction and thereby improve translation.
Preclinical data are essential for decision‑making in radiopharmaceutical development, and all stakeholders require a robust evidence base. However, each stakeholder brings a slightly different lens to both designing studies and interpreting the resulting evidence.
This is the first in a series of radiopharmaceutical blogs from Dr Juliana Maynard. Juliana is an expert imaging scientist with over 20 years’ experience in nuclear medicine and translational imaging.
In this blog, Dr Phil Auckland details how MDC has established a reproducible CRISPR-Cas9 pipeline and generated new tools to better inform nanotherapeutic design
Nanotherapeutics often fail because of Endosomal entrapment. In this blog by Dr Phil Auckland, we explore how MDC are using real-time imaging to reveal why.
Accelerating analgesic development through human-specific in vitro systems
See how we can help support you with your next drug discovery project.
Speak to us
